
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp reported strong financial performance with General Surgery sales growing by 8.7% to $206.9 million, surpassing consensus expectations, while Orthopedic Surgery sales increased by 2.4% to $139.0 million, also exceeding projections. The company demonstrated improved operating efficiency, with an operating margin increase of 280 basis points year-over-year to 18.6%, fueled by gross margin expansion and effective operating leverage. Additionally, Conmed's gross margin reached 57.6%, reflecting a 120 basis point year-over-year improvement and slightly exceeding previous estimates, indicating a solid trajectory for future profitability amid ongoing supply chain challenges.
Bears say
The financial outlook for Conmed Corp is negative, primarily due to anticipated revenue growth slowing to 4% or less, stemming from weaker AirSeal and Buffalo Filter sales and potential new product launch failures. Additionally, management has issued 2025 revenue and earnings per share guidance that falls below consensus estimates, citing ongoing supply chain challenges that are expected to impact margins. Furthermore, substantial revisions to revenue projections for 2025 and 2026 indicate a potential decline in the company's financial performance, reflecting a broader concern regarding its growth trajectory and overall profitability.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares